Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal

A method of increasing the bioavailability of recombinant human insulin isophane in a patient, said method comprising:

• administering recombinant human insulin isophane in a hepatocyte-targeting composition, said composition comprising free recombinant human insulin isophane and recombinant human insulin isophane associated with a water insoluble target molecule complex,
• wherein said complex comprises multiple linked individual units and a supra-molecular lipid construct matrix containing a negative charge, said multiple linked individual units comprising:
• (a) a bridging component selected from the group consisting of a transition element, an inner transition element, a neighbor element of said transition element and a mixture of any of the foregoing elements, (b) a complexing component, provided that when said transition element is chromium, a chromium target molecule complex is created,
• wherein said multiple linked individual units are combined with said supra-molecular lipid construct matrix, wherein said insulins are associated with said target molecule complex that contains a negative charge;
• thereby the association between recombinant human insulin isophane and said water insoluble target molecule complex is altered within said patient to form new structures associated with said recombinant human insulin isophane, wherein said new structures are present in soluble and insoluble forms and are delivered to sites of insulin activity.